Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Oncolytic viral immunotherapy HF-10 active in trials in patients with superficial cancers

Nov. 20, 2015

Prima BioMed plans trial combining IMP-321 and immune checkpoint inhibitor

Nov. 20, 2015

Lilly initiates phase I study of LY-3127804 with ramucirumab for advanced solid tumors

Nov. 20, 2015

Ludwig Cancer Research and Cancer Research Institute partner with Targovax

Nov. 20, 2015

Merck KGaA and Pfizer receive FDA breakthrough therapy designation for avelumab

Nov. 19, 2015

Immune responses seen with DNA-based vaccine INO-3112 in head and neck squamous cell carcinoma

Nov. 19, 2015

Phase II results with hepcortespenlisimut-L in HCC lead to phase III trial

Nov. 18, 2015

FDA accepts BMS's sBLA for nivolumab in RCC

Nov. 17, 2015

FDA first to approve Darzalex for multiple myeloma

Nov. 17, 2015

Researchers present long-term survival data on AVX-701 cancer vaccine

Nov. 17, 2015

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...